Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.